Cutler Group LP Ultragenyx Pharmaceutical Inc. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$34.92 - $46.66 $35,269 - $47,126	1,010 New	1,010 $36,000
Q4 2020 Jan 21, 2021	BUY	$84.4 - $177.39 $34,688 - $72,907	411 New	411 $56,000
Q4 2019 Feb 06, 2020	SELL	$36.08 - $45.83 $7,216 - $9,166	-200 Closed	0 $0
Q3 2019 Oct 28, 2019	SELL	$42.5 - $63.11 $12,750 - $18,933	-300 Reduced 60.0%	200 $8,000
Q2 2019 Aug 09, 2019	BUY	$54.93 - $74.36 $27,465 - $37,180	500 New	500 $31,000
Q1 2019 May 10, 2019	SELL	$39.87 - $69.36 $72,603 - $126,304	-1,821 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$38.89 - $77.3 $6,961 - $13,836	-179 Reduced 8.95%	1,821 $79,000
Q3 2018 Nov 07, 2018	SELL	$71.81 - $90.15 $10,771 - $13,522	-150 Reduced 6.98%	2,000 $152,000
Q2 2018 Aug 10, 2018	BUY	$48.54 - $85.31 $97,080 - $170,620	2,000 Added 1333.33%	2,150 $165,000
Q1 2018 May 11, 2018	SELL	$44.33 - $58.52 $4,433 - $5,852	-100 Reduced 40.0%	150 $7,000
Q4 2017 Jan 17, 2018	SELL	$43.54 - $57.32 $98,531 - $129,715	-2,263 Reduced 90.05%	250 $11,000
Q3 2017 Oct 17, 2017	BUY	$49.79 - $66.32 $125,122 - $166,662	2,513	2,513 $133,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.